## CURIS INC

Form 10-Q/A
March 31, 2006
Table of Contents

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 10-Q/A
Amendment No. 1
(Mark one)
$x$ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

## CURIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

| (State or Other Jurisdiction of | (I.R.S. Employer |
| :---: | :---: |
| Incorporation or Organization) | Identification No.) |
| 61 Moulton Street |  |
| Cambridge, Massachusetts | 02138 |
| (Address of Principal Executive Offices) | (Zip Code) |

## Registrant s Telephone Number, Including Area Code: (617) 503-6500

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes .. No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer .. Accelerated filer x Non-accelerated filer ..

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): .. Yes $x$ No

As of November 11, 2005, there were $49,339,994$ shares of the Registrant s common stock outstanding.

## Table of Contents

## EXPLANATORY NOTE:

This Amendment No. 1 on Form 10-Q/A is being filed to restate the September 30, 2005 and December 31, 2004 consolidated balance sheets contained herein to correct amounts reported in prepaid expenses and other current assets, deposits and other assets, short-term and long-term deferred revenues, additional paid-in capital, and accumulated deficit; and to restate the consolidated statements of operations for the three- and nine-month periods ended September 30, 2005 and September 30, 2004, to correct amounts reported in gross revenues and research and development expenses. As a result of these restatements, amounts in the consolidated statements of cash flows for the nine-month periods ended September 30, 2005 and 2004 have also been corrected.

A summary of the effects of this restatement to our financial statements included within this Amendment No. 1 on Form 10-Q/A is presented at Note 3, Restatement of Financial Statements.

This Amendment No. 1 amends Part I, Items 1 and 2 and Part II, Item 6 of the Quarterly Report on Form 10-Q for the three- and nine-month periods ended September 30, 2005. This Amendment No. 1 continues to reflect circumstances as of the date of the original filing of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and we have not updated the disclosures contained herein to reflect events that occurred at a later date, except for items related to the restatement or where otherwise indicated.

We do not anticipate filing amended Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q for any periods prior to the first quarter of 2005. Our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q from the second quarter of 2003 through fiscal 2004 have not been revised to reflect the restatement and the consolidated financial statements contained in those reports should not be relied upon. Instead, the consolidated financial statements for fiscal 2004 and 2003 included in our Annual Report on Form 10-K for the fiscal period ended December 31, 2005 should be relied upon.

## INDEX

Page
Number
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of September 30, 2005 and December 31, 2004 (unaudited and as restated) ..... 4
Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2005 and 2004 (unaudited and as restated) ..... 5
Consolidated Statements of Cash Flows for the nine months ended September 30, 2005 and 2004 (unaudited and as restated) ..... 6
Notes to Unaudited Condensed Consolidated Financial Statements ..... 7
Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations ..... 25
PART II. OTHER INFORMATION
Item 6. Exhibits ..... 55
SIGNATURE ..... 56

## Table of Contents

## Item 1. FINANCIAL STATEMENTS

## CURIS, INC. AND SUBSIDIARY

## CONDENSED CONSOLIDATED BALANCE SHEETS

## (unaudited)



## Edgar Filing: CURIS INC - Form 10-Q/A

| Commitments |  |  |
| :---: | :---: | :---: |
| Stockholders Equity: |  |  |
| Common stock, \$0.01 par value |  |  |
| $125,000,000$ shares authorized; $49,333,495$ and $48,285,788$ shares issued and outstanding, respectively, at September 30, 2005 and 48,565,120 and 47,517,413 shares issued and outstanding, respectively, at December 31, 2004 | 493,335 | 485,652 |
| Additional paid-in capital | 718,740,861 | 714,831,427 |
| Treasury stock (at cost, 1,047,707 shares at September 30, 2005 and December 31, 2004) | $(891,274)$ | $(891,274)$ |
| Deferred compensation | $(386,699)$ | $(834,157)$ |
| Accumulated deficit | $(678,689,593)$ | $(665,199,001)$ |
| Accumulated other comprehensive loss | $(35,368)$ | $(80,644)$ |
| Total stockholders equity | 39,231,262 | 48,312,003 |
|  | \$ 60,643,572 | \$ 67,332,042 |

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

## CURIS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)

|  | Three Months Ended <br> September 30, |  | Nine Months Ended September 30, |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2005 | 2004 | 2005 | 2004 |
|  | (as restated) | (as restated) | (as restated) | (as restated) |
| REVENUES: |  |  |  |  |
| License fees | \$ 258,544 | \$ 68,100 | \$ 582,243 | \$ 174,365 |
| Research and development contracts | 2,626,072 | 1,100,881 | 7,358,750 | 2,289,033 |
| Substantive Milestones |  |  | 250,000 | 50,000 |
| Gross Revenues | 2,884,616 | 1,168,981 | 8,190,993 | 2,513,398 |
| Contra-revenues from co-development with Genentech | $(819,491)$ |  | $(5,697,993)$ |  |
| Net Revenues | 2,065,125 | 1,168,981 | 2,493,000 | 2,513,398 |
| COSTS AND EXPENSES: |  |  |  |  |
| Research and development | 3,691,261 | 3,324,079 | 10,409,583 | 9,380,846 |
| General and administrative | 1,832,802 | 2,138,070 | 6,141,013 | 6,460,769 |
| Amortization of intangible assets | 18,768 | 18,768 | 56,304 | 56,304 |
| Total costs and expenses | 5,542,831 | 5,480,917 | 16,606,900 | 15,897,919 |
| Loss from operations | $(3,477,706)$ | $(4,311,936)$ | (14,113,900) | (13,384,521) |
| OTHER INCOME (EXPENSE): |  |  |  |  |
| Interest income | 319,208 | 116,358 | 861,869 | 332,530 |
| Other income |  | 39,500 | 24,958 | 232,845 |
| Interest expense | $(92,843)$ | $(102,474)$ | $(263,519)$ | $(306,753)$ |
| Total other income, net | 226,365 | 53,384 | 623,308 | 258,622 |
| Net loss | \$ (3,251,341) | \$ (4,258,552) | \$ (13,490,592) | \$ (13,125,899) |
| Net loss per common share (basic and diluted) | \$ (0.07) | \$ (0.10) | \$ (0.28) | \$ (0.32) |
| Weighted average common shares (basic and diluted) | 48,178,626 | 41,620,123 | 47,998,663 | 41,398,656 |
| Net loss | \$ $(3,251,341)$ | \$ (4,258,552) | \$ (13,490,592) | \$ (13,125,899) |
| Unrealized gain (loss) on marketable securities | 25,585 | 23,330 | 45,276 | $(35,829)$ |
| Comprehensive loss | \$ $(3,225,756)$ | \$ (4,235,222) | \$ (13,445, 316) | \$ (13,161,728) |

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

## CURIS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

|  | Nine Months Ended September 30, |  |
| :---: | :---: | :---: |
|  | 2005 | 2004 |
|  | (as restated) | (as restated) |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| Net loss | \$ (13,490,592) | \$ (13,125,899) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Depreciation and amortization | 668,720 | 833,045 |
| Stock-based compensation expense | 193,004 | 1,058,678 |
| Non-cash interest on notes payable | 152,478 | 293,549 |
| Amortization of intangible assets | 56,304 | 56,304 |
| Decrease/increase in long-term receivables |  |  |
| Changes in current assets and liabilities: |  |  |
| Accounts receivable | $(799,680)$ | $(396,368)$ |
| Prepaid expenses and other assets | $(188,761)$ | $(101,713)$ |
| Accounts payable and accrued liabilities | 1,363,494 | 251,008 |
| Deferred contract revenue | 2,500,936 | 3,546,348 |
|  |  |  |
| Total adjustments | 3,946,495 | 5,540,851 |
|  |  |  |
| Net cash used in operating activities | $(9,544,097)$ | $(7,585,048)$ |
|  | - |  |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| Purchase of marketable securities | (24,904,025) | $(17,383,387)$ |

